PubMed Health⌕ Search

Biomedical subjects

M Schaffrinski

Publications and source records attributed to M Schaffrinski.

5 recordsLinked to original sources

[Fungus detection--a simple method. Screening with optical brighteners].

Histological detection of mycosis can be laboriously but can be easier by a simple fluorescenceoptical method. Optical brighteners (e.g. blankophor, calcofluor) make it possible to detect fungus cell walls without significant background fluorescence of resident tissue. Mycosis can be detected even in cytological slides after maceration by brighteners.

Contrast Media↗

Vital staining of fungal elements in deep-seated mycotic lesions during experimental murine mycoses using the parenterally applied optical brightener Blankophor.

Optical brighteners of the diaminostilbene type are fluorescent dyes which are popular diagnostic tools in the mycology laboratory. While these dyes are conventionally used for the in vitro diagnosis of mycoses, their low toxicity and chemical reactivity have led us to investigate their potential use for in vivo staining of fungal elements in mycotic tissue. In mice we have established deep-seated candidiasis, cryptococcosis, aspergillosis and zygomycosis, as well as coccidioidomycosis, histoplasmosis and blastomycosis. After establishment of infection, which mostly required immunosuppression, a single dose of 100 microl of an aqueous solution (2.2 x 10(-4) M) of the optical brightener Blankophor P fluessig (4,4'-Bis [(4-anilino-6-substituted-1,3,5-triazine-2-yl) amino] stilbene-2,2'-disulfonic acid) was injected by the tail vein and the animals were sacrificed 1 h later. Sections of freshly prepared target organs were directly subjected to epifluorescence microscopy using an appropriate filter kit. In most cases, fluorescent fungal elements could be detected in the murine tissue. There was little evidence for uptake of the dye by non-infected tissues. It is suggested that radioactive labeling may render parenteral Blankophor suitable for radiographic localization of deep-seated mycotic foci in the host.

Animals↗

[Laboratory diagnostic peculiarities of mycoses in immunosuppressed patients].

Domestic invasive mycoses are typically present as secondary diseases in patients definitely immunocompromised. This truth should not obscure the fact that a transient overload of the immune system, e.g. in the polytrauma patients, may likewise favour the development of mycoses. The two groups of patients show a comparable course of infection and, to some extent, diagnostic signs: surveillance cultures and monitoring of antibodies are more helpful with trauma patients and less reliable in the typically immunocompromised patients. In the latter, however, antigen tests may yield more reliable results than in the trauma patients. The different functional capacities of the immune system in the two groups of patients may also affect the appearance of fungal elements, particularly of aspergilli, in secretions and biopsies.

Adult↗

Modulation of experimental systemic murine candidosis by intravenous pepstatin.

The effect of intravenous pepstatin-A on systemic candidosis in NWNI mice was investigated. True solutions of the inhibitor proved ineffective due to a very fast clearance. Pepstatin was effective as a crystal suspension (0.69 mg in 0.1 ml saline) which produced serum inhibitory activity for greater than 29 h. From the intravenously applied suspension, pepstatin was taken up predominantly into the liver, no inhibitor being taken up by the kidneys. The suspension was protective if it was injected once before the mice were infected and repeatedly following infection. It was also effective if it was administered concomitantly with the infecting agent and thereafter. The suspension was ineffective if it was only given once before infection, and it proved to be detrimental if it was given only after infection. The results support previous findings (2), suggesting a role of fungal proteinase early in the adherence of Candida to host epithelia. Our results also suggest an inhibition of lysosomal cathepsin-D in vivo by pepstatin, which prohibits a parenteral therapeutic use of nonmodified pepstatin A.

Animals↗